ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

EIGR Eiger BioPharmaceuticals Inc

1.725
0.00 (0.00%)
02 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Eiger BioPharmaceuticals Inc EIGR NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 1.725 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.725 1.725
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
01/4/202410:12GLOBEEiger BioPharmaceuticals Files for Voluntary Chapter 11..
11/3/202415:03EDGAR2Form 8-K - Current report
24/1/202415:59EDGAR2Form 8-K - Current report
18/1/202416:49PRNUSEiger and Partner, AnGes, Receive Approval for Zokinvy®..
08/1/202406:00EDGAR2Form 8-K - Current report
04/1/202407:45EDGAR2Form 8-K - Current report
04/1/202407:00PRNUSEiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse..
11/12/202315:01EDGAR2Form DEF 14A - Other definitive proxy statements
04/12/202305:01EDGAR2Form SC 13D/A - General statement of acquisition of..
01/12/202315:02EDGAR2Form PRE 14A - Other preliminary proxy statements
24/11/202305:01EDGAR2Form SC 13D - General statement of acquisition of beneficial..
13/11/202315:01EDGAR2Form 8-K - Current report
09/11/202315:27EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202315:14EDGAR2Form 8-K - Current report
09/11/202315:05PRNUSEiger BioPharmaceuticals Reports Third Quarter 2023..
02/11/202320:54EDGAR2Form SC 13D/A - General statement of acquisition of..
02/11/202320:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/10/202315:51EDGAR2Form 3 - Initial statement of beneficial ownership of..
20/10/202315:29EDGAR2Form SC 13D - General statement of acquisition of beneficial..
28/9/202315:54EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/9/202316:17DJNEiger BioPharmaceuticals to Discontinue Chronic Hepatitis..
12/9/202315:42EDGAR2Form 8-K - Current report
12/9/202315:05PRNUSEiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon..
05/9/202320:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202320:35EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/9/202315:05PRNUSEiger BioPharmaceuticals to Present at H.C. Wainwright 25th..
15/8/202305:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/8/202315:24EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202315:09EDGAR2Form 8-K - Current report
14/8/202315:05PRNUSEiger BioPharmaceuticals Reports Second Quarter 2023..
28/7/202315:17EDGAR2Form 8-K - Current report
07/7/202315:35EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/7/202316:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/6/202315:16EDGAR2Form 8-K - Current report
29/6/202307:00PRNUSEiger BioPharmaceuticals to Focus on Metabolic Diseases with..
28/6/202315:05PRNUSEiger BioPharmaceuticals to Host Business Update Call..
11/5/202315:00PRNUSEiger BioPharmaceuticals Reports First Quarter 2023..

Su Consulta Reciente

Delayed Upgrade Clock